Selvita SA
WSE:SLV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (40.5), the stock would be worth zł19.96 (43% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 71 | zł35 |
0%
|
| 3-Year Average | 40.5 | zł19.96 |
-43%
|
| 5-Year Average | 42.9 | zł21.12 |
-40%
|
| Industry Average | 91.5 | zł45.11 |
+29%
|
| Country Average | 11.3 | zł5.55 |
-84%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
zł908.7m
|
/ |
Oct 2025
zł10.7m
|
= |
|
|
zł908.7m
|
/ |
Dec 2025
zł5.4m
|
= |
|
|
zł908.7m
|
/ |
Dec 2026
zł33.6m
|
= |
|
|
zł908.7m
|
/ |
Dec 2027
zł53.6m
|
= |
|
|
zł908.7m
|
/ |
Dec 2028
zł91.1m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| PL |
S
|
Selvita SA
WSE:SLV
|
642.4m PLN | 71 | -222 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD | 2 361.7 | 4 280.5 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
175.6B USD | 24.6 | 26.2 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.4B USD | 26 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 39.4 | 46.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
34.3B CHF | 25.7 | -119.7 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
298.9B CNY | 16.3 | 15.6 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.3B USD | 21.8 | 25.1 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.5B USD | 38.6 | 47.5 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.3B USD | 17.1 | 20.1 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.7B USD | 24.4 | 29.6 |
Market Distribution
| Min | 0.5 |
| 30th Percentile | 8.1 |
| Median | 11.3 |
| 70th Percentile | 16 |
| Max | 313.7 |
Other Multiples
Selvita SA
Glance View
Selvita SA engages in the discovery, regulatory studies, as well as research and development. The company is headquartered in Krakow, Woj. Malopolskie and currently employs 878 full-time employees. The company went IPO on 2019-10-16. The firm is engaged in providing multidisciplinary solutions supporting customers and projects within area of drug discovery, regulatory studies, as well as research and development. The company offers its clients drug discovery support at every stage of the early discovery phase up to preclinical research, from target validation up to the selection of a clinical candidate. Also, it offers services at every stage of the drug discovery process in the field of drug testing and bioanalytical analyses, from development and validation of methods, stability studies, to routine quality control testing. The firm cooperates with numerous research institutes and universities from Europe and the United States.
